Chattem Q2
This article was originally published in The Rose Sheet
Executive Summary
Selsun Blue sales advanced 57% and Gold Bond revenues rose 11% in the second quarter (ended May 31), Chattem reports June 19. Sales for the dandruff shampoo reflect the fact the brand was owned by Chattem for two of the three months in the corresponding 2002 quarter as well as strong advertising and increased distribution, according to the firm. Gold Bond sales were driven by the shipment of three new products and continued strength of the foot care portion of the business, Chattem says. Overall company sales increased 8% to $63.6 mil. in Q2 and income before an accounting change gained 33% to $7.5 mil...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.